GREAVES et al., 1988 - Google Patents

Clindamycin versus metronidazole in the treatment of bacterial vaginosis

GREAVES et al., 1988

Document ID
10896158879528933714
Author
GREAVES W
CHUNGAFUNG J
MORRIS B
HAILE A
TOWNSEND J
Publication year
Publication venue
Obstetrics & Gynecology

External Links

Snippet

One hundred forty-three women with complaints of vaginitis were assigned to receive either 500 mg of metronidazole twice daily for 7 days or clindamycin 300 mg twice daily for 7 days. There was no significant difference in the failure rate between patients treated with …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
GREAVES et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis
Avonts et al. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study
VEJTORP et al. Bacterial vaginosis: a double‐blind randomized trial of the effect of treatment of the sexual partner
HILLIER et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis
Vujic et al. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study
Moore et al. Bacteria in the transfer catheter tip influence the live-birth rate after in vitro fertilization
Miller et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium
SCHMITT et al. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole
Swedberg et al. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis
Rees The treatment of pelvic inflammatory disease
Sweet et al. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline
Eschenbach et al. A dose-duration study of metronidazole for the treatment of nonspecific vaginosis
Spencer et al. Bacterial isolates associated with pelvic inflammatory disease among female patients attending some hospitals in abuja, Nigeria.
Hay Recurrent bacterial vaginosis
KOUTSKY et al. Persistence of Mycoplasma hominis after Therapy: Importance of Tetracydine Resistance and of Coexisting Vaginal Flora
McDONALD et al. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomized controlled trial
Koumantakis et al. Vulvovaginitis during childhood and adolescence
Imseis et al. The microbiologic effect of digital cervical examination
Durfee et al. Ineffectiveness of erythromycin for treatment of Haemophilus vaginalis-associated vaginitis: possible relationship to acidity of vaginal secretions
WØLNER-HANSSEN et al. Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline
Tidwell et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis
Wathne et al. Erythromycin versus metronidazole in the treatment of bacterial vaginosis
Olowe et al. Prevalence and pattern of bacterial isolates in cases of pelvic inflammatory disease patients at a tertiary hospital in Osogbo, Nigeria
Weström et al. The Effect of Antibiotic Therapy on Mycoplasma in the Female Genital Tract: In vitro and in vivo Studies on the Sensitivity of Mycoplasma hominis and T-Mycoplasmas to Tetracyclines and other Antibiotics
Eggert-Kruse et al. Effects of antimicrobial therapy on sperm-mucus interaction